Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa (PIONEER)
A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Researchers at the University of Pittsburgh Medical Center are recruiting Retinitis Pigmentosa patients for an investigation of a gene therapy designed to impart a gene to correct the disease. The treatment would require a single intravitreal (into the retina) injection of the drug, a genetically modified and harmless virus. The patient would also undergo a light-stimulation treatment and follow up for 1 year.
- Be 18 to 75 years of age
- Have diagnosis of non-syndromic RP
- Not have a prior vitrectomy or vitreomacular surgery
THE STUDY INVOLVES:
- Prescreening tests to confirm eligibility of the patient to participate.
- Intravitreal injection of the gene therapy at one of several dose levels.
- Undergo light-stimulation therapy and follow up for 1 year.
LOCATIONS AND CONTACTS:
The study site is at the UPMC Eye Center in Pittsburgh, PA. Map.
Barrett Katz, MD | +1 646 831 3799 | [email protected]
Or go online: